Silexion Therapeutics Corp

Explanatory Note

The financial statements included in this Part I, Item 1 of this Quarterly Report as of, and for the three and six-month periods ended on June 30, 2024 are those of Silexion and not New Silexion. The determination to include Silexion’s financial statements in lieu of New Silexion’s was based on the fact that only Silexion and not the Company was an active entity with actual operations during the three and six-month periods, and as of the balance sheet date, that are required to be presented in this Quarterly Report. Until the consummation of the Business Combination, which occurred on August 15, 2024 (which was after the balance sheet date of, and the three and six - month periods ended on June 30, 2024), the Company had no operations and had been formed for the sole purpose of entering into the Business Combination and serving as the publicly-traded registrant resulting from the Business Combination. Consequently, the Company’s financial condition and results of operations as of, and for the three and six-month periods ended on June 30, 2024 are not material to an understanding of the financial condition and results of operations of the registrant, and have therefore been omitted from this Quarterly Report. For the subject period and as of the subject balance sheet date, only the financial information of Silexion, as the accounting acquirer in the Business Combination and the predecessor entity to the Company from an accounting perspective, is material to an understanding of the financial condition and results of operations of the registrant.

SILEXION THERAPEUTICS LTD.

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2024

SILEXION THERAPEUTICS LTD.

INTERIM FINANCIAL STATEMENTS

JUNE 30, 2024

(Unaudited)

TABLE OF CONTENTS